New research indicates that individuals who come off new weight-loss injections like Wegovy and Mounjaro may regain reduced body mass much more quickly than those who halt traditional lifestyle regimens.
Published data in a prominent medical journal shows that while overweight individuals frequently drop a large proportion of their body weight while on the medication, the mass returns at an average rate of 0.8 kg per month upon discontinuation.
"Individuals buying these medications must be aware of the risk of quick weight regain when the therapy is stopped," cautioned expert Dr. Susan Jebb.
Such speed of recovery implies a reversion to original mass within about 18 months.
Analyzing Therapies
The study, which reviewed 37 of studies involving over 9,000 of participants, contrasted the outcomes of these new drugs with conventional dieting.
Scientists emphasize that individuals who shed pounds through dieting typically see a slower creep back—perhaps 0.1 kg a month—after stopping.
The Reason for the Quick Rebound
Nutrition scientists believe the mode of action of the injections accounts for the heightened rebound.
These medications imitate a body's own chemical called glucagon-like peptide-1, which controls feelings of fullness.
"Sustained high doses of the hormone concentrations several times higher than the body's typical production could lead to the system to generate a reduced amount of its endogenous hormone, and could diminish sensitivity to its actions," noted Dr. Adam Collins, a nutrition researcher.
"Withdrawal of this GLP-1 'fix' means hunger is uncontrolled, making excessive eating a significant risk."
A Chronic Condition?
Medical guidelines suggest the injections for individuals with obesity-related health risks, alongside recommended lifestyle changes.
A number of clinicians say that, considering the high risk of weight regain, the therapy should be considered long-term.
This view is supported by pharmaceutical companies, who state that the findings "highlight the chronic nature of excess weight," comparing it to managing conditions like high blood pressure.
Patient Accounts
Individuals who have discontinued the medication describe a intense resurgence of cravings.
"It was like a switch activating and I was suddenly ravenous," said one woman.
This challenge is compounded if users have not established lasting lifestyle or habit changes during treatment.
Widespread Adoption
Figures indicate that millions of people in the UK have tried weight-loss jabs in the last 12 months, with interest continuing to grow.
- Use is more common among women than males.
- The 40s and 50s age group shows the highest level of interest.
- A large proportion obtain the medications through private healthcare rather than public health services.
Ultimately, experts emphasize that while these medications are powerful tools for shedding pounds, they are not a standalone fix and maintained weight loss likely depends on combined lifestyle changes.
